FN1 and cancer: Cancer-specific survival (CSS) after three and five years were 62.4% and 57.9%, respectively, for IgG-Fn-positive, and 79.5% and 72.4%, respectively, for IgG-Fn-negative patients (HR 1.59, 95% CI 1.09–2.33; p = 0.02) (Fig 1B).